CLAIMS:

1. Use of a loop diuretic in the manufacture of a medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection an effective amount of the loop diuretic in a total volume of about 1 mL or less of a liquid pharmaceutical formulation.

2. The use of claim 1, wherein the effective amount of the loop diuretic in the total volume of the liquid pharmaceutical formulation is about 1 mg to about 100 mg.

3. The use of claim 1 or 2, wherein the concentration of the loop diuretic in the total volume of the liquid pharmaceutical formulation is about 2 mg/mL to about 100 mg/mL.

4. The use of any one of claims 1-3, wherein the total urine output of the human about 6 hours after administration is complete is about 600 mL to about 5000 mL.

5. The use of any one of claims 1-4, wherein the total urine output of the human about 8 hours after administration is complete is about 600 mL to about 5300 mL.

6. The use of any one of claims 1-5, wherein the total urine output of the human about 12 hours after administration is complete is about 600 mL to about 5500 mL.

7. The use of any one of claims 1-6, wherein the loop diuretic is bumetanide, furosemide, or torsemide.

8. Use of furosemide in the manufacture of a medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection an effective amount of the furosemide in a total volume of about 1 mL or less of a liquid pharmaceutical formulation.

9. The use of claim 8, wherein the effective amount of furosemide in the total volume of the liquid pharmaceutical formulation is about 40 mg to about 80 mg.

10. The use of claim 8 or 9, wherein the concentration of furosemide in the total volume of the liquid pharmaceutical formulation is about 80 mg/mL.

11. The use of any one of claims 8-10, wherein the total volume of the liquid pharmaceutical formulation is about 0.5 mL or about 1 mL.

12. Use of furosemide in the manufacture of a medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection about 80 mg of furosemide in a total volume of about 1 mL of a liquid pharmaceutical formulation.

13. Use of furosemide in the manufacture of a medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection about 40 mg of furosemide in a total volume of about 0.5 mL of a liquid pharmaceutical formulation.

14. The use of any one of claims 8-13, wherein the furosemide C_{max} in plasma of the human is about 1500 ng/mL to about 9800 ng/mL.

15. The use of any one of claims 8-14, wherein the furosemide AUC_{last} in plasma of the human is about 4400 h*ng/mL to about 31700 h*ng/mL.

16. The use of any one of claims 8-15, wherein the furosemide AUC_{inf} in plasma of the human is about 4500 h*ng/mL to about 33400 h*ng/mL.

17. The use of any one of claims 8-16, wherein the total urine output of the human about 6 hours after administration is complete is about 600 mL to about 5000 mL.

18. The use of any one of claims 8-17, wherein the total urine output of the human about 8 hours after administration is complete is about 600 mL to about 5300 mL.

19. The use of any one of claims 8-18, wherein the total urine output of the human about 12 hours after administration is complete is about 600 mL to about 5500 mL.

20. Use of furosemide in the manufacture of a medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection about 80 mg furosemide in a total volume of about 1 mL of a liquid pharmaceutical formulation, wherein one or more of the following:

the furosemide C_{max} in plasma of the human is about 3000 ng/mL to about 9800 ng/mL;

the furosemide AUC_{last} in plasma of the human is about 8800 h*ng/mL to about 31700 h*ng/mL;

the furosemide AUC_{inf} in plasma of the human is about 8900 h*ng/mL to about 33400 h*ng/mL;

the total urine output of the human about 6 hours after administration is complete is about 1200 mL to about 5000 mL;

the total urine output of the human about 8 hours after administration is complete is about 1200 mL to about 5300 mL; and

the total urine output of the human about 12 hours after administration is complete is about 1200 mL to about 5500 mL.

21. Use of furosemide in the manufacture of a medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection about 80 mg furosemide in a total volume of about 1 mL of a liquid pharmaceutical formulation, wherein:

the furosemide C_{max} in plasma of the human is about 3000 ng/mL to about 9800 ng/mL;

the furosemide AUC_{last} in plasma of the human is about 8800 h*ng/mL to about 31700 h*ng/mL;

the furosemide AUC_{inf} in plasma of the human is about 8900 h*ng/mL to about 33400 h*ng/mL;

the total urine output of the human about 6 hours after administration is complete is about 1200 mL to about 5000 mL;

the total urine output of the human about 8 hours after administration is complete is about 1200 mL to about 5300 mL; and

the total urine output of the human about 12 hours after administration is complete is about 1200 mL to about 5500 mL.

22. Use of furosemide in the manufacture of a medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection about 40 mg furosemide in a total volume of about 0.5 mL of a liquid pharmaceutical formulation, wherein one or more of the following:

the furosemide C_{max} in plasma of the human is about 1500 ng/mL to about 4900 ng/mL;

the furosemide AUC_{last} in plasma of the human is about 4400 h*ng/mL to about 15850 h*ng/mL;

the furosemide AUC_{inf} in plasma of the human is about 4500 h*ng/mL to about 16700 h*ng/mL;

the total urine output of the human about 6 hours after administration is complete is about 600 mL to about 2500 mL;

the total urine output of the human about 8 hours after administration is complete is about 600 mL to about 2650 mL; and

the total urine output of the human about 12 hours after administration is complete is about 600 mL to about 2750 mL.

23. Use of furosemide in the manufacture of medicament for treating a condition selected from the group consisting of congestion due to fluid overload, edema, and hypertension, in a human in need thereof, wherein the human is to be administered via subcutaneous injection about 40 mg furosemide in a total volume of about 0.5 mL of a liquid pharmaceutical formulation, wherein:

the furosemide C_{max} in plasma of the human is about 1500 ng/mL to about 4900 ng/mL;

the furosemide AUC_{last} in plasma of the human is about 4400 h*ng/mL to about 15850 h*ng/mL;

the furosemide AUC_{inf} in plasma of the human is about 4450 h*ng/mL to about 16700 h*ng/mL;

the total urine output of the human about 6 hours after administration is complete is about 600 mL to about 2500 mL;

the total urine output of the human about 8 hours after administration is complete is about 600 mL to about 2650 mL; and

the total urine output of the human about 12 hours after administration is complete is about 600 mL to about 2750 mL.

24. The use of any one of claims 1-23, wherein the subject is to be administered the total volume over a period of equal to or less than 30 secs.

25. The use of any one of claims 1-24, wherein the subject is to be administered the total volume from an autoinjector.

26. The use of any one of claims 1-25, wherein the liquid pharmaceutical formulation further comprises a pharmaceutically acceptable buffer, optionally wherein the pharmaceutically acceptable buffer comprises tromethamine, or a pharmaceutically acceptable salt thereof.

27. The use of any one of claims 1-26, wherein the liquid pharmaceutical formulation has a pH of about 7.2 to about 8.

28. The use of any one of claims 1-27, wherein the liquid pharmaceutical formulation further comprises one or more pharmaceutically acceptable excipients, optionally wherein the one or more pharmaceutically acceptable excipients is selected from benzyl alcohol, sodium hydroxide, sodium chloride, hydrochloric acid, and combinations thereof.

29. The use of any one of claims 1-28, wherein the human is an adult human, optionally wherein the adult human is 45 to 80 years of age.

30. The use of claim 29, wherein the adult human has New York Heart Association (NYHA) Class II, Class III, or Class IV chronic heart failure, liver disease or impairment, or renal disease or impairment.

31. The use of claim 29 or 30, wherein the adult human displays reduced responsiveness to oral diuretics before beginning subcutaneous administration according to the method.

32. The use of any one of claims 1-31, wherein the edema is associated with congestive heart failure, cirrhosis of the liver, or renal disease, optionally wherein the renal disease is nephrotic syndrome.